IMEL Biotherapeutics

IMEL Biotherapeutics is focused on developing cell-based therapies for patients suffering from mitochondrial disorders. Founded in 2019 and headquartered in Waltham, Massachusetts, the company employs a proprietary technology that replaces dysfunctional mitochondria with healthy ones. This innovative approach allows healthcare practitioners to treat various mitochondrial genetic and age-related disorders, effectively reprogramming the functionality of affected cells. By addressing the root causes of these conditions, IMEL Biotherapeutics aims to provide improved therapeutic options for patients.